Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Dominik Selleslag; Stefan Suciu; Giovanna Meloni; Petra Muus; Constantijn J.M. Halkes; Adriano Venditti; Safaa M. Ramadan; Hans Pruijt; Liv Meert; Marco Vignetti; Jean Pierre Marie; Sébastian Wittnebel; Theo de Witte; Sergio Amadori; Roelof Willemze; Frédéric Baron

doi:10.3324/haematol.2016.153130

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Dominik Selleslag, Stefan Suciu, Giovanna Meloni, Petra Muus, Constantijn J.M. Halkes, Adriano Venditti, Safaa M. Ramadan, Hans Pruijt, Liv Meert, Marco Vignetti, Jean Pierre Marie, Sébastian Wittnebel, Theo de Witte, Sergio Amadori, Roelof Willemze, Frédéric Baron

Istituto Europeo di Oncologia

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e47-e51
Journal	Haematologica
Volume	102
Issue number	2
DOIs	https://doi.org/10.3324/haematol.2016.153130
Publication status	Published - Jan 1 2017

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2016.153130

Cite this

Selleslag, D., Suciu, S., Meloni, G., Muus, P., Halkes, C. J. M., Venditti, A., Ramadan, S. M., Pruijt, H., Meert, L., Vignetti, M., Marie, J. P., Wittnebel, S., de Witte, T., Amadori, S., Willemze, R., & Baron, F. (2017). Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial. Haematologica, 102(2), e47-e51. https://doi.org/10.3324/haematol.2016.153130

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome : Combined phase I/II results of the EORTC/GIMEMA AML-14A trial. / Selleslag, Dominik; Suciu, Stefan; Meloni, Giovanna; Muus, Petra; Halkes, Constantijn J.M.; Venditti, Adriano; Ramadan, Safaa M.; Pruijt, Hans; Meert, Liv; Vignetti, Marco; Marie, Jean Pierre; Wittnebel, Sébastian; de Witte, Theo; Amadori, Sergio; Willemze, Roelof; Baron, Frédéric.

In: Haematologica, Vol. 102, No. 2, 01.01.2017, p. e47-e51.

Research output: Contribution to journal › Letter › peer-review

Selleslag, D, Suciu, S, Meloni, G, Muus, P, Halkes, CJM, Venditti, A, Ramadan, SM, Pruijt, H, Meert, L, Vignetti, M, Marie, JP, Wittnebel, S, de Witte, T, Amadori, S, Willemze, R & Baron, F 2017, 'Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial', Haematologica, vol. 102, no. 2, pp. e47-e51. https://doi.org/10.3324/haematol.2016.153130

Selleslag D, Suciu S, Meloni G, Muus P, Halkes CJM, Venditti A et al. Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial. Haematologica. 2017 Jan 1;102(2):e47-e51. https://doi.org/10.3324/haematol.2016.153130

Selleslag, Dominik ; Suciu, Stefan ; Meloni, Giovanna ; Muus, Petra ; Halkes, Constantijn J.M. ; Venditti, Adriano ; Ramadan, Safaa M. ; Pruijt, Hans ; Meert, Liv ; Vignetti, Marco ; Marie, Jean Pierre ; Wittnebel, Sébastian ; de Witte, Theo ; Amadori, Sergio ; Willemze, Roelof ; Baron, Frédéric. / Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome : Combined phase I/II results of the EORTC/GIMEMA AML-14A trial. In: Haematologica. 2017 ; Vol. 102, No. 2. pp. e47-e51.

@article{ffa89dbc182d4466a8b3d20c1c0a3b99,

title = "Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial",

author = "Dominik Selleslag and Stefan Suciu and Giovanna Meloni and Petra Muus and Halkes, {Constantijn J.M.} and Adriano Venditti and Ramadan, {Safaa M.} and Hans Pruijt and Liv Meert and Marco Vignetti and Marie, {Jean Pierre} and S{\'e}bastian Wittnebel and {de Witte}, Theo and Sergio Amadori and Roelof Willemze and Fr{\'e}d{\'e}ric Baron",

year = "2017",

month = jan,

day = "1",

doi = "10.3324/haematol.2016.153130",

language = "English",

volume = "102",

pages = "e47--e51",

journal = "Haematologica",

issn = "0390-6078",

publisher = "NLM (Medline)",

number = "2",

}

TY - JOUR

T1 - Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome

T2 - Combined phase I/II results of the EORTC/GIMEMA AML-14A trial

AU - Selleslag, Dominik

AU - Suciu, Stefan

AU - Meloni, Giovanna

AU - Muus, Petra

AU - Halkes, Constantijn J.M.

AU - Venditti, Adriano

AU - Ramadan, Safaa M.

AU - Pruijt, Hans

AU - Meert, Liv

AU - Vignetti, Marco

AU - Marie, Jean Pierre

AU - Wittnebel, Sébastian

AU - de Witte, Theo

AU - Amadori, Sergio

AU - Willemze, Roelof

AU - Baron, Frédéric

PY - 2017/1/1

Y1 - 2017/1/1

UR - http://www.scopus.com/inward/record.url?scp=85011573612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011573612&partnerID=8YFLogxK

U2 - 10.3324/haematol.2016.153130

DO - 10.3324/haematol.2016.153130

M3 - Letter

AN - SCOPUS:85011573612

VL - 102

SP - e47-e51

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 2

ER -